Bayer создала отдельный бизнес-блок Ruveon для управления производством глифосата в США

Bayer has announced the consolidation of its US glyphosate business into a dedicated unit, Ruveon LLC. The St Louis-based business, which remains part of Bayer, will oversee all aspects of the company’s US glyphosate operations, including pricing, production, logistics and go-to-market strategy. The move forms part of Bayer Crop Science’s five-year restructuring plan and comes at a pivotal moment for the glyphosate market. The announcement followed just one day after Bayer asked Washington to impose duties on Chinese glyphosate imports, arguing that “the domestic glyphosate business as it stands today is not sustainable”. The request has drawn criticism from some farmer groups concerned that tariffs could raise herbicide costs. A mature market facing new pressures Ruveon’s creation comes amid mounting pressure from multiple directions. On the commercial front, Bayer faces intense competition from low-cost Chinese manufacturers that dominate global glyphosate production. At the same time, Roundup remains under legal and regulatory scrutiny despite Bayer securing a significant victory last week when the US Supreme Court blocked thousands of state-court lawsuits alleging the company failed to warn users that glyphosate causes cancer. Meanwhile, the wider crop protection industry is increasingly focused on biologicals, digital agriculture and next-generation chemistries that promise more targeted and sustainable approaches to crop management. Against that backdrop, Ruveon appears less like a retreat from glyphosate and more like an attempt to create a structure better suited to managing a mature, highly competitive and politically sensitive business. Bayer itself emphasised the need for a specialised approach. “Ruveon is expected to be a more nimble and well-positioned player within its commodity-based market, which requires a specialized approach to address competitive dynamics,” the company said. Bayer doubles down on glyphosate – but on different terms Despite investing heavily in future technologies, Bayer is keen to underline that glyphosate remains a cornerstone of modern agriculture. “Glyphosate remains an essential tool for farmers worldwide as it helps them produce more food on existing farmland by controlling weeds efficiently and cost-effectively,” a Bayer spokesperson told AgNavigator. The spokesperson added that glyphosate supports reduced tillage practices that can improve soil health and reduce greenhouse gas emissions. However, Bayer also acknowledged that no single technology can meet all future farming needs. The company said growers will increasingly require a mix of synthetic crop protection products, biological solutions, innovative seeds and digital technologies to manage productivity, sustainability and resistance challenges. That position reflects a broader industry reality. While biologicals continue to attract investment and momentum, they have not yet replaced glyphosate’s combination of efficacy, reliability, scalability and affordability across many major cropping systems. Strategic separation The key question raised by Ruveon is whether it represents a vote of confidence in glyphosate’s long-term future or simply a way to manage a mature business while Bayer pursues the next wave of innovation. The answer appears to be both. By creating a standalone operation focused exclusively on glyphosate, Bayer is clearly signalling that the herbicide remains strategically important. Yet it is also ring-fencing a business that faces unique competitive, legal and reputational challenges from the rest of its innovation-driven Crop Science portfolio. The may also create optionality for future corporate restructuring. Reuters has reported that the new unit is fuelling investor hopes that the German group could move closer to structural changes, including spin-offs or divestments, long sought by some shareholders. As Brian Naber, head of Crop Science North America and Australia/New Zealand, put it: “Ruveon’s launch is a sign of our ongoing commitment to excellence in the glyphosate market.” Led by Bayer veteran Alfonso Alba Ordóñez as chief executive and Steve Knodle as head of commercial operations, Ruveon has been designed to operate with greater focus and agility in a fiercely contested market. For Bayer, the message is that glyphosate still matters. But in an era increasingly defined by biologicals, digital agriculture and sustainability-driven innovation, the company believes it needs a different organisational model to ensure the product remains profitable and competitive.